In 2020 Dr Malinda Itchins graduated from her doctoral studies investigating drug resistance in ALK-rearranged non-small cell lung cancer both preclinically, and via a TOGA clinical trial in progress, ALKternate.
Malinda is the Lung Cancer Chair for the Clinical Oncology of Australia (COSA) Council. She is Primary Investigator on a number of lung cancer clinical trials and her research focus to date has been in patterns of care, the real-world experience and drug resistance in oncogene driven lung cancers. She is passionate about the evolution of precision medicine in lung cancer.